ArticleLeukemia2013

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).

V Sardnal et al.PubMed ↗Publisher ↗

No numbers read from the abstract.